Breaking News Instant updates and real-time market news.

IMMU

Immunomedics

$19.51

0.725 (3.86%)

07:47
05/17/18
05/17
07:47
05/17/18
07:47

Immunomedics data could support breakthrough designation, says Wells Fargo

Wells Fargo analyst Jim Birchenough believes the abstract data for IMMU132 in hormone-receptor breast cancer could support breakthrough designation and a potential fast-to-market path for an indication that is up to three times bigger than the advanced indication of triple negative breast cancer. The analyst reiterates an Overweight rating on shares of Immunomedics.

IMMU Immunomedics
$19.51

0.725 (3.86%)

11/14/17
JEFF
11/14/17
NO CHANGE
Target $16
JEFF
Buy
Jefferies disagrees with yesterday's selloff in Immunomedics
Immunomedics closed down 19% yesterday largely due to interim overall survival data for IMMU-132 and concerns the FDA will require Phase III overall survival data for approval, Jefferies analyst Matthew Andrews tells investors in a research note. The analyst disagrees, and keeps a Buy rating on the shares with a $16 price target. The progression-free survival is the Phase III Special Protocol Assessment's primary endpoint, while the overall survival data may ultimately be confounded by patients' use of other drugs after progression, Andrews tells investors in a research note. Precedent for objective response rate/duration of response exists with FDA breakthrough therapy approvals of 12 solid tumor drugs, some with less robust efficacy than IMMU-132, the analyst adds.
11/14/17
COWN
11/14/17
NO CHANGE
Target $15
COWN
Outperform
Immunomedics drug survival rate disappointing but approval likely, says Cowen
Cowen analyst Phil Nadeau said the overall survival rate for Immunomedics' IMMU-132 showed a decrease, which was disappointing, but the response rate is still well above the current standard of care. As a result, the analyst believes it still appears likely to get accelerated FDA approval. Nadeau reiterated his Outperform rating and $15 price target on Immunomedics shares.
12/06/17
JEFF
12/06/17
NO CHANGE
JEFF
Buy
Immunomedics breast cancer data continue to look 'very solid,' says Jefferies
Jefferies analyst Matthew Andrews says the totality of Immunomedics' Phase II breast cancer data for IMMU-132 "continue to look very solid." Importantly, there was no clinically meaningful decrease in objective response rate per blinded central review, Andrews tells investors in a research note after the company announced updated results. The analyst reiterates a Buy rating and believes the data is sufficient to support FDA accelerated approval.
01/24/18
JEFF
01/24/18
NO CHANGE
Target $22
JEFF
Buy
Immunomedics price target raised to $22 from $16 at Jefferies
Jefferies analyst Matthew Andrews raised his price target for Immunomedics to $22 saying his analysis suggests a 98% FDA approval probability of IMMU-132. The shares could be worth $27 on approval, Andrews tells investors in a research note. He keeps a Buy rating on Immunomedics.

TODAY'S FREE FLY STORIES

VKTX

Viking Therapeutics

$19.47

9.07 (87.21%)

08:28
09/19/18
09/19
08:28
09/19/18
08:28
Recommendations
Viking Therapeutics analyst commentary  »

Viking Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ZEAL

Zealand Pharma

$18.48

0.4 (2.21%)

, NVO

Novo Nordisk

$47.44

-0.2 (-0.42%)

08:27
09/19/18
09/19
08:27
09/19/18
08:27
Recommendations
Zealand Pharma, Novo Nordisk analyst commentary  »

Zealand Pharma price…

ZEAL

Zealand Pharma

$18.48

0.4 (2.21%)

NVO

Novo Nordisk

$47.44

-0.2 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLK

Westlake Chemical

$83.89

-1.82 (-2.12%)

08:26
09/19/18
09/19
08:26
09/19/18
08:26
Downgrade
Westlake Chemical rating change  »

Westlake Chemical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALLK

Allakos

$44.88

0.95 (2.16%)

08:25
09/19/18
09/19
08:25
09/19/18
08:25
Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call »

Biotech Analysts, along…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

SPWR

SunPower

$7.55

0.97 (14.74%)

, ENPH

Enphase Energy

$4.35

0.48 (12.40%)

08:24
09/19/18
09/19
08:24
09/19/18
08:24
Recommendations
SunPower, Enphase Energy, First Solar analyst commentary  »

Tariff exemption a…

SPWR

SunPower

$7.55

0.97 (14.74%)

ENPH

Enphase Energy

$4.35

0.48 (12.40%)

FSLR

First Solar

$49.56

1.81 (3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

08:23
09/19/18
09/19
08:23
09/19/18
08:23
Conference/Events
JPMorgan to hold a summit »

India Investor Summit…

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:21
09/19/18
09/19
08:21
09/19/18
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:20
09/19/18
09/19
08:20
09/19/18
08:20
General news
Senate Judiciary vote on Kavanaugh Supreme Court vote cancelled, CNN reports »

The Senate Judiciary…

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
09/19/18
09/19
08:20
09/19/18
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKTA

Okta

$69.82

0.3 (0.43%)

, ZS

Zscaler

$39.79

-0.455 (-1.13%)

08:20
09/19/18
09/19
08:20
09/19/18
08:20
Conference/Events
William Blair to hold a tour »

Cybersecurity Bus Tour…

OKTA

Okta

$69.82

0.3 (0.43%)

ZS

Zscaler

$39.79

-0.455 (-1.13%)

PANW

Palo Alto Networks

$234.07

2.1 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

  • 10

    Oct

  • 11

    Oct

  • 16

    Oct

  • 06

    Dec

  • 10

    Dec

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
09/19/18
09/19
08:20
09/19/18
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$207.47

0.89 (0.43%)

08:20
09/19/18
09/19
08:20
09/19/18
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:20
09/19/18
09/19
08:20
09/19/18
08:20
General news
U.S. housing starts preview: »

U.S. housing starts…

08:20
09/19/18
09/19
08:20
09/19/18
08:20
General news
U.S. current account preview: »

U.S. current account…

XLK

Technology Select Sector SPDR

$74.46

0.45 (0.61%)

08:19
09/19/18
09/19
08:19
09/19/18
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$74.89

0.52 (0.70%)

08:19
09/19/18
09/19
08:19
09/19/18
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$116.98

1.5 (1.30%)

08:19
09/19/18
09/19
08:19
09/19/18
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$59.68

0.065 (0.11%)

08:19
09/19/18
09/19
08:19
09/19/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$54.37

-0.11 (-0.20%)

08:18
09/19/18
09/19
08:18
09/19/18
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$54.72

-0.25 (-0.45%)

08:18
09/19/18
09/19
08:18
09/19/18
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWKS

Skyworks

$86.82

0.58 (0.67%)

08:18
09/19/18
09/19
08:18
09/19/18
08:18
Recommendations
Skyworks analyst commentary  »

Skyworks underperformance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$93.71

0.5 (0.54%)

08:18
09/19/18
09/19
08:18
09/19/18
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIVB

Civista Bancshares

$22.95

-0.23 (-0.99%)

08:18
09/19/18
09/19
08:18
09/19/18
08:18
Upgrade
Civista Bancshares rating change  »

Civista Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$170.24

0.68 (0.40%)

08:18
09/19/18
09/19
08:18
09/19/18
08:18
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$262.87

1.89 (0.72%)

08:17
09/19/18
09/19
08:17
09/19/18
08:17
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.